Coronary Artery Disease Doubles Excess Mortality in Patients With Heart Failure With Reduced Ejection Fraction

Nanna Anker1, Kevin K W Olesen1,2, Pernille G Thrane1,2

  • 1Department of Cardiology Aarhus University Hospital Aarhus Denmark.

Insights

Coronary artery disease (CAD) significantly increases mortality in heart failure with reduced ejection fraction (HFrEF) patients. Assessing CAD is crucial for prognosis, as it doubles excess mortality compared to the general population.

Area of Science:

  • Cardiology
  • Clinical Research
  • Public Health

Background:

  • Coronary artery disease (CAD) assessment varies globally in heart failure with reduced ejection fraction (HFrEF) patients.
  • Limited data exist on the long-term impact of CAD in this population.
  • This study investigates the association between CAD and mortality in HFrEF patients undergoing coronary angiography.

Purpose of the Study:

  • To examine the association between coronary artery disease (CAD) and all-cause mortality.
  • To compare mortality rates between HFrEF patients with and without CAD.
  • To compare mortality in HFrEF patients with CAD against a matched general population.

Main Methods:

  • Utilized Danish registries to identify HFrEF patients (EF ≤40%) who underwent coronary angiography (2003-2016).
  • Estimated 10-year cumulative incidence and adjusted hazard ratios (aHR) for all-cause death.
  • Compared HFrEF patients with CAD to those without CAD and to an age/sex-matched general population (1:5 ratio).

Main Results:

  • Included 3294 HFrEF patients (44% with CAD) and 16,365 general population individuals.
  • Patients with HFrEF and CAD had higher 10-year mortality (55%) than those without CAD (33%).
  • CAD presence doubled excess 10-year mortality in HFrEF patients compared to the general population (55% vs. 26%).

Conclusions:

  • Coronary artery disease (CAD) presence and extent are strongly linked to mortality in HFrEF patients.
  • CAD assessment is vital for improving prognostication in HFrEF.
  • Identifying and managing CAD in HFrEF patients can significantly impact long-term outcomes.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
Imbalances in Cardiac Output01:23

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to...
1.2K
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
315
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
271
Cardiac Output I:Effect of Heart Rate on Cardiac Output01:19

Cardiac Output I:Effect of Heart Rate on Cardiac Output

Cardiac Output
Cardiac output (CO) refers to the total amount of blood ejected by one of the ventricles in liters per minute (L/min). In a resting adult, CO ranges from 5 to 6 L/min, adjusting according to the body's metabolic requirements.
Effect of Heart Rate on Cardiac Output
Cardiac output adapts to metabolic demands during stress, physical activity, or illness. The autonomic nervous system regulates heart rate via the sinoatrial node. The parasympathetic nervous system decreases heart...
485